Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 205 to 208 of 208 entries
Sorted by: Best Match Show Resources per page
Autologous hematopoietic cell transplantation during second or subsequent complete remission of acute promyelocytic leukemia: a prognostic factor analysis.

Bone marrow transplantation

Yanada M, Ota S, Mukae J, Nara M, Kako S, Nishikawa A, Uchida N, Sawa M, Nakano N, Onizuka M, Kanda Y, Ichinohe T, Atsuta Y, Yano S.
PMID: 34645925
Bone Marrow Transplant. 2022 Jan;57(1):78-82. doi: 10.1038/s41409-021-01501-9. Epub 2021 Oct 13.

Autologous hematopoietic cell transplantation (HCT) is an effective therapy for patients with relapsed acute promyelocytic leukemia (APL). However, it remains unclear whether this procedure is equally effective for certain groups of patients. To address this question, we analyzed 296...

Cite
Yanada M, Ota S, Mukae J, et al. Autologous hematopoietic cell transplantation during second or subsequent complete remission of acute promyelocytic leukemia: a prognostic factor analysis. Bone Marrow Transplant. 2021;57(1):78-82doi: 10.1038/s41409-021-01501-9.
Yanada, M., Ota, S., Mukae, J., Nara, M., Kako, S., Nishikawa, A., Uchida, N., Sawa, M., Nakano, N., Onizuka, M., Kanda, Y., Ichinohe, T., Atsuta, Y., & Yano, S. (2022). Autologous hematopoietic cell transplantation during second or subsequent complete remission of acute promyelocytic leukemia: a prognostic factor analysis. Bone marrow transplantation, 57(1), 78-82. https://doi.org/10.1038/s41409-021-01501-9
Yanada, Masamitsu, et al. "Autologous hematopoietic cell transplantation during second or subsequent complete remission of acute promyelocytic leukemia: a prognostic factor analysis." Bone marrow transplantation vol. 57,1 (2022): 78-82. doi: https://doi.org/10.1038/s41409-021-01501-9
Yanada M, Ota S, Mukae J, Nara M, Kako S, Nishikawa A, Uchida N, Sawa M, Nakano N, Onizuka M, Kanda Y, Ichinohe T, Atsuta Y, Yano S. Autologous hematopoietic cell transplantation during second or subsequent complete remission of acute promyelocytic leukemia: a prognostic factor analysis. Bone Marrow Transplant. 2022 Jan;57(1):78-82. doi: 10.1038/s41409-021-01501-9. Epub 2021 Oct 13. PMID: 34645925.
Copy Download .nbib Format: NLM
Clinical characteristics of intractable or persistent hiccups and nausea associated with herpes zoster.

Clinical neurology and neurosurgery

Hayashi Y, Ueda N, Shibata H, Yaguchi T, Yoshikura N, Yamada M, Kimura A, Inuzuka T, Shimohata T.
PMID: 34119896
Clin Neurol Neurosurg. 2021 Aug;207:106751. doi: 10.1016/j.clineuro.2021.106751. Epub 2021 Jun 08.

AIM: Intractable or persistent hiccups and nausea (IHN) are rarely associated with herpes zoster (HZ-IHN). We aimed to identify the clinical characteristics of HZ-IHN by comparing them with those of neuromyelitis optica spectrum disorder associated with IHN (NMOSD-IHN).METHODS: We...

Cite
Hayashi Y, Ueda N, Shibata H, et al. Clinical characteristics of intractable or persistent hiccups and nausea associated with herpes zoster. Clin Neurol Neurosurg. 2021;207:106751doi: 10.1016/j.clineuro.2021.106751.
Hayashi, Y., Ueda, N., Shibata, H., Yaguchi, T., Yoshikura, N., Yamada, M., Kimura, A., Inuzuka, T., & Shimohata, T. (2021). Clinical characteristics of intractable or persistent hiccups and nausea associated with herpes zoster. Clinical neurology and neurosurgery, 207106751. https://doi.org/10.1016/j.clineuro.2021.106751
Hayashi, Yuichi, et al. "Clinical characteristics of intractable or persistent hiccups and nausea associated with herpes zoster." Clinical neurology and neurosurgery vol. 207 (2021): 106751. doi: https://doi.org/10.1016/j.clineuro.2021.106751
Hayashi Y, Ueda N, Shibata H, Yaguchi T, Yoshikura N, Yamada M, Kimura A, Inuzuka T, Shimohata T. Clinical characteristics of intractable or persistent hiccups and nausea associated with herpes zoster. Clin Neurol Neurosurg. 2021 Aug;207:106751. doi: 10.1016/j.clineuro.2021.106751. Epub 2021 Jun 08. PMID: 34119896.
Copy Download .nbib Format: NLM
The evaluation of factors affecting antibody response after administration of the BNT162b2 vaccine: a prospective study in Japan.

PeerJ

Mitsunaga T, Ohtaki Y, Seki Y, Yoshioka M, Mori H, Suzuka M, Mashiko S, Takeda S, Mashiko K.
PMID: 34721989
PeerJ. 2021 Oct 13;9:e12316. doi: 10.7717/peerj.12316. eCollection 2021.

The aim of this study was to evaluate the antibody reaction after administration of the BNT162b2 vaccine, and to reveal the factors that affect antibody production. This prospective study was carried out in the Association of EISEIKAI Medical and...

Cite
Mitsunaga T, Ohtaki Y, Seki Y, et al. The evaluation of factors affecting antibody response after administration of the BNT162b2 vaccine: a prospective study in Japan. PeerJ. 2021;9:e12316doi: 10.7717/peerj.12316.
Mitsunaga, T., Ohtaki, Y., Seki, Y., Yoshioka, M., Mori, H., Suzuka, M., Mashiko, S., Takeda, S., & Mashiko, K. (2021). The evaluation of factors affecting antibody response after administration of the BNT162b2 vaccine: a prospective study in Japan. PeerJ, 9e12316. https://doi.org/10.7717/peerj.12316
Mitsunaga, Toshiya, et al. "The evaluation of factors affecting antibody response after administration of the BNT162b2 vaccine: a prospective study in Japan." PeerJ vol. 9 (2021): e12316. doi: https://doi.org/10.7717/peerj.12316
Mitsunaga T, Ohtaki Y, Seki Y, Yoshioka M, Mori H, Suzuka M, Mashiko S, Takeda S, Mashiko K. The evaluation of factors affecting antibody response after administration of the BNT162b2 vaccine: a prospective study in Japan. PeerJ. 2021 Oct 13;9:e12316. doi: 10.7717/peerj.12316. eCollection 2021. PMID: 34721989; PMCID: PMC8520395.
Copy Download .nbib Format: NLM
The differential effect of disease status at allogeneic hematopoietic cell transplantation on outcomes in acute myeloid and lymphoblastic leukemia.

Annals of hematology

Yanada M, Konuma T, Yamasaki S, Mizuno S, Hirabayashi S, Nishiwaki S, Uchida N, Doki N, Tanaka M, Ozawa Y, Sawa M, Eto T, Kawakita T, Ota S, Fukuda T, Onizuka M, Kimura T, Atsuta Y, Kako S, Yano S.
PMID: 34477952
Ann Hematol. 2021 Dec;100(12):3017-3027. doi: 10.1007/s00277-021-04661-2. Epub 2021 Sep 03.

This study aimed to compare the effect of disease status at the time of allogeneic hematopoietic cell transplantation (HCT) on post-transplant outcomes between acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Japanese nationwide registry data for 6901 patients...

Cite
Yanada M, Konuma T, Yamasaki S, et al. The differential effect of disease status at allogeneic hematopoietic cell transplantation on outcomes in acute myeloid and lymphoblastic leukemia. Ann Hematol. 2021;100(12):3017-3027doi: 10.1007/s00277-021-04661-2.
Yanada, M., Konuma, T., Yamasaki, S., Mizuno, S., Hirabayashi, S., Nishiwaki, S., Uchida, N., Doki, N., Tanaka, M., Ozawa, Y., Sawa, M., Eto, T., Kawakita, T., Ota, S., Fukuda, T., Onizuka, M., Kimura, T., Atsuta, Y., Kako, S., & Yano, S. (2021). The differential effect of disease status at allogeneic hematopoietic cell transplantation on outcomes in acute myeloid and lymphoblastic leukemia. Annals of hematology, 100(12), 3017-3027. https://doi.org/10.1007/s00277-021-04661-2
Yanada, Masamitsu, et al. "The differential effect of disease status at allogeneic hematopoietic cell transplantation on outcomes in acute myeloid and lymphoblastic leukemia." Annals of hematology vol. 100,12 (2021): 3017-3027. doi: https://doi.org/10.1007/s00277-021-04661-2
Yanada M, Konuma T, Yamasaki S, Mizuno S, Hirabayashi S, Nishiwaki S, Uchida N, Doki N, Tanaka M, Ozawa Y, Sawa M, Eto T, Kawakita T, Ota S, Fukuda T, Onizuka M, Kimura T, Atsuta Y, Kako S, Yano S. The differential effect of disease status at allogeneic hematopoietic cell transplantation on outcomes in acute myeloid and lymphoblastic leukemia. Ann Hematol. 2021 Dec;100(12):3017-3027. doi: 10.1007/s00277-021-04661-2. Epub 2021 Sep 03. PMID: 34477952.
Copy Download .nbib Format: NLM
Showing 205 to 208 of 208 entries